Clinical trials: Sarcoidosis
Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung
A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension
This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks…
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
- Trial name
- NCT07613216
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cosmos Rx, Inc
Pulmonary Sarcoidosis
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment.
- Trial name
- NCT05415137
- Testing
- Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg
- Where
- 91 sites in United States, Brazil and 7 more
- Volunteers
- 268 people
- Sponsor
- aTyr Pharma, Inc.
Sarcoidosis, Pulmonary
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).
- Trial name
- RESOLVE-Lung (NCT05314517)
- Testing
- Namilumab
- Where
- 47 sites in United States, Belgium and 5 more
- Volunteers
- 107 people
- Sponsor
- Kinevant Sciences GmbH
Pulmonary Sarcoidosis
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects…
- Trial name
- NCT06205121
- Testing
- OATD-01
- Where
- 28 sites in United States, Denmark and 6 more
- Volunteers
- 96 people
- Sponsor
- Molecure S.A.
Cutaneous Sarcoidosis
A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
- Trial name
- BEACON (NCT06978725)
- Testing
- Oral Brepocitinib
- Where
- 44 sites in United States, Australia and 1 more
- Volunteers
- 168 people
- Sponsor
- Priovant Therapeutics, Inc.
Neoplasms
Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days
Although Neopharm has terminated its sponsorship of this study, it is continuing under the sponsorship of the NCI. Please see "Experimental Drug SS1(dsFv)-PE38 to Treat Cancer" (Study ID number 010011).
- Trial name
- NCT00024674
- Testing
- SS1(dsFv)-PE38
- Where
- United States
- Sponsor
- INSYS Therapeutics Inc
Lung Cancer, Emphysema
CryoSpray Ablation(tm)Thoracic Patient Registry
The purpose of this study is to create a patient registry to collect and analyze information on subjects treated with the CryoSpray Ablation™ System post-510K approval.
- Conditions
- Lung Cancer, Emphysema, Chronic Bronchitis, COPD
- Trial name
- NCT00785239
- Sponsor
- CSA Medical, Inc.
Sarcoidosis
A Study of Infliximab in Patients With Sarcoidosis
The purpose of this study is to evaluate the safety and effectiveness of infliximab (Remicade) in patients with Chronic Sarcoidosis.
- Trial name
- NCT00073437
- Testing
- Infliximab
- Volunteers
- 139 people
- Sponsor
- Centocor, Inc.
Pulmonary Sarcoidosis
A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis
The study proposes to evaluate the safety, tolerability, and efficacy of PD 0360324 in subjects with chronic pulmonary sarcoidosis inadequately treated with standard of care therapies.
- Trial name
- NCT01732211
- Testing
- PD 0360324, Normal Saline for injection
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Stage 2 Pulmonary Sarcoidosis, Stage 3 Pulmonary Sarcoidosis
Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis
The primary objective of the study is to assess the safety and tolerability of a single dose of PDA001 (given twice) in subjects with Stage II or III Pulmonary Sarcoidosis (PS) who are refractory to one or more of the following…
- Trial name
- NCT01440192
- Testing
- PDA001 (cenplacel-L)
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- Celularity Incorporated
Pulmonary Sarcoidosis
Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
The purpose of this proof of concept study was to determine whether CMK389 displays the safety and efficacy profile to support further development in chronic pulmonary sarcoidosis.
- Trial name
- NCT04064242
- Testing
- CMK389
- Where
- 22 sites in United States, Czechia and 4 more
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Sarcoidosis Associated Pulmonary Hypertension
LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 (Inhaled Sirolimus) in Adults with Sarcoidosis Associated Pulmonary Hypertension (SAPH)
- Trial name
- NCT07886554
- Testing
- LAM-001
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- IRulya Therapeutics Inc.
Sarcoidosis, Pulmonary
Acthar Gel in Participants With Pulmonary Sarcoidosis
The purpose of this study is to find out if Acthar Gel is safe and effective to treat pulmonary sarcoidosis. Participants will be randomly assigned (like flipping a coin) to receive a shot under their skin of Acthar Gel or a…
- Trial name
- PULSAR (NCT03320070)
- Testing
- Acthar Gel
- Where
- 29 sites in United States
- Volunteers
- 55 people
- Sponsor
- Mallinckrodt
Pulmonary Hypertension, Pulmonary Fibrosis
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis
A phase 2b, open label study to assess the safety and efficacy of increasing doses of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis and sarcoidosis on long term oxygen therapy followed by a long term…
- Conditions
- Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
- Trial name
- NCT03727451
- Testing
- iNO
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bellerophon